Product How it works Pricing Blog FAQ About Contact
United States

Galectin Therapeutics (NASDAQ: GALT) stock: the official figures

Galectin Therapeutics (GALECTIN THERAPEUTICS INC.) is listed on Nasdaq under the ticker GALT and belongs to the health care sector. In fiscal 2025 it reported a net loss of $30.8m, according to the annual accounts it filed with the regulator.

Identifiers for Galectin Therapeutics: SEC CIK 1133416.

Fiscal 2025 figures

Consolidated annual accounts of Galectin Therapeutics, in millions of US dollars
Item20252024Change
Operating profit−$20.1m−$42.4m—
Net profit−$30.8m−$47.0m—
Earnings per share−$0.48−$0.76—
Total assets$19.5m$17.5m+11.6%
Equity−$127.9m−$104.8m—
Cash$17.7m$15.1m+17.2%
Operating cash flow−$23.9m−$41.8m—

Margins are calculated from the filed figures: operating profit and net profit over revenue.

10 fiscal years

Net profit, in millions of US dollars-21.42016-16.22017-13.92018-13.32019-23.52020-30.52021-38.82022-41.12023-47.02024-30.82025
Fiscal yearOperating profitNet profitEarnings per shareDocument
2025−$20.1m−$30.8m−$0.48Annual report
2024−$42.4m−$47.0m−$0.76Annual report
2023−$38.1m−$41.1m−$0.74Annual report
2022−$38.4m−$38.8m−$0.65Annual report
2021−$30.2m−$30.5m−$0.52Annual report
2020−$23.4m−$23.5m−$0.41Annual report
2019−$13.4m−$13.3m—Annual report
2018−$13.6m−$13.9m—Annual report
2017−$16.2m−$16.2m—Annual report
2016−$21.5m−$21.4m—Annual report

The full income statement, balance sheet and cash flow statement are in the annual accounts of Galectin Therapeutics. Purchases and sales by its executives and directors are in insider transactions.

Frequently asked questions about Galectin Therapeutics

How much did Galectin Therapeutics earn in fiscal 2025?
Galectin Therapeutics reported a net loss of $30.8m for fiscal 2025. The year before it reported a net loss of $47.0m.
What are the earnings per share of Galectin Therapeutics?
They were −$0.48 in fiscal 2025, compared with −$0.76 the year before.
Where is Galectin Therapeutics listed?
Galectin Therapeutics is listed on Nasdaq under the ticker GALT and belongs to the health care sector.
Where do the figures for Galectin Therapeutics come from?
From the annual report (Form 10-K) that Galectin Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

The annual accounts come from the annual report (Form 10-K) that Galectin Therapeutics files with the SEC, the US securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.